麝香通心滴丸联合沙库巴曲缬沙坦片对急性心肌梗死pci术后患者心功能及心室重构的影响

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Acute myocardial infarction after PCI complicated with early-onset heart failure (n=40). Intervention: Shexiang Tongxin Dropping Pills plus Sacubitril/Valsartan and standard therapy vs. Standard therapy including Sacubitril/Valsartan (50-200 mg twice daily), dual antiplatelet therapy, statin, and beta-blocker. Primary outcome: NYHA functional class improvement (≥1 grade) at 3 months (p=0.028).

Q: What does this research mean for the field?

Combining Shexiang Tongxin dropping pills with sacubitril/valsartan improves cardiac function and attenuates adverse ventricular remodeling in acute myocardial infarction patients with early-onset heart failure following PCI. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

张萍萍

doi:10.37155/2717-5693-0702-4

January 1, 2026内科诊疗与进展Open Access

麝香通心滴丸联合沙库巴曲缬沙坦片对急性心肌梗死pci术后患者心功能及心室重构的影响

View Full Paper

Ask AI

Bookmark

Share

Why the study?

The effect of combining Shexiang Tongxin dropping pills with sacubitril/valsartan on cardiac function and ventricular remodeling after PCI for AMI required investigation.

Does adding Shexiang Tongxin Dropping Pills to standard medical therapy including sacubitril/valsartan improve cardiac function and inhibit left ventricular remodeling in patients with early-onset heart failure after PCI for acute myocardial infarction?

Key Points

To evaluate the efficacy and safety of Shexiang Tongxin dropping pills combined with sacubitril/valsartan on cardiac function and ventricular remodeling in patients with heart failure following percutaneous coronary intervention for acute myocardial infarction.
Prospective, single-center, randomized, open-label trial enrolling 40 patients undergoing percutaneous coronary intervention for acute myocardial infarction with early-onset heart failure at Jinyun County People's Hospital between June 2025 and March 2026.
Patients were randomly allocated to a control group (n=20) receiving guideline-directed medical therapy including sacubitril/valsartan, or an observation group (n=20) receiving sacubitril/valsartan combined with Shexiang Tongxin dropping pills (2 pills three times daily) for 3 months.
At 3 months, BNP decreased more in the observation group than in the control group (286.3±64.7 pg/mL vs. 462.5±85.4 pg/mL, t=7.463, P=0.014), and NYHA functional class improvement of ≥1 grade was significantly higher (80.0% [16/20] vs. 50.0% [10/20], χ²=4.800, P=0.028).
Left ventricular ejection fraction increased significantly more in the observation group compared to controls (52.5±5.4% vs. 48.3±4.9%, P=0.026), alongside greater reductions in left ventricular end-diastolic dimension (51.2±3.7 mm vs. 53.8±4.0 mm, P=0.031) and left ventricular mass index (108.5±11.6 g/m² vs. 118.4±13.1 g/m², P=0.018).
Major adverse cardiovascular events occurred in 5.0% (1/20) of the observation group and 20.0% (4/20) of the control group (P=0.342), with no serious drug-related adverse reactions reported in either group.

Study Design

Type

RCT (n=40)

Blinding

Open-label

Randomization

Random number table method

Multicenter

No

Structured PICO

Does adding Shexiang Tongxin Dropping Pills to standard medical therapy including sacubitril/valsartan improve cardiac function and inhibit left ventricular remodeling in patients with early-onset heart failure after PCI for acute myocardial infarction?

P

Population

40 adults (mean age ~63.5 years, 27.5% female) with first acute myocardial infarction complicated by early-onset heart failure (Killip class II-III) after successful primary PCI, treated and followed for 3 months.

I

Intervention

Shexiang Tongxin Dropping Pills (35 mg per pill, 2 pills per dose, 3 times daily, sublingual or oral) for 3 months, added to guideline-directed standard medical therapy including sacubitril/valsartan (starting at 50 mg bid, titrated up to 200 mg bid or maximum tolerated dose), dual antiplatelet therapy (aspirin 100 mg qd + clopidogrel 75 mg qd or ticagrelor 90 mg bid), statin (atorvastatin 20-40 mg qd or rosuvastatin 10-20 mg qd), and beta-blocker (metoprolol succinate 23.75-190 mg qd or bisoprolol 1.25-10 mg qd).

C

Comparator

Guideline-directed standard medical therapy alone for 3 months, initiated within 24-72h post-PCI, including sacubitril/valsartan (starting at 50 mg bid, titrated to 200 mg bid or maximum tolerated dose), dual antiplatelet therapy (aspirin 100 mg qd + clopidogrel 75 mg qd or ticagrelor 90 mg bid for at least 12 months), statin (atorvastatin 20-40 mg qd or rosuvastatin 10-20 mg qd), and beta-blocker (metoprolol succinate 23.75-190 mg qd or bisoprolol 1.25-10 mg qd).

O

Outcome

Cardiac function (serum BNP via chemiluminescence and NYHA functional class improvement ≥1 grade independently assessed by two attending physicians) and left ventricular remodeling parameters (LVEF by Simpson's method, LVEDD, LVESD, and LVMI measured by echocardiography) at 3 months.surrogate

Main Result

Absolute Event Rate: 80% vs 50%

p-value: p=0.028

Limitations

Small sample size (40 patients), resulting in no statistically significant difference in MACE incidence
Short follow-up duration of only 3 months, leaving long-term hard endpoints unknown
Single-center, open-label design
Short follow-up duration of only 3 months, leaving long-term hard clinical endpoints unknown

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

In patients with early-onset heart failure following PCI for acute myocardial infarction, adding Shexiang Tongxin Dropping Pills to standard therapy including sacubitril/valsartan significantly improves NYHA class, lowers BNP, and attenuates left ventricular remodeling at 3 months without increasing adverse events.

Abstract

张萍萍（浙江丽水缙云县人民医院）目的：探讨麝香通心滴丸联合沙库巴曲缬沙坦片对急性心肌梗死（AMI）经皮冠状动脉介入治疗（PCI）术后患者心功能及心室重构的影响。方法：纳入40例AMI行PCI且合并早发心力衰竭的患者，随机分为对照组（20例，常规西药含沙库巴曲缬沙坦片）和观察组（20例，沙库巴曲缬沙坦片联合加用麝香通心滴丸，2丸/次，3 次/d），治疗3个月。比较两组治疗前后BNP、NYHA分级、LVEF、LVEDD、LVESD、LVMI。结果：观察组BNP、 LVEDD、LVESD、LVMI均低于对照组，LVEF、NYHA改善率均高于对照组（P < 0.05）；两组均无严重不良反应。结论：联合麝香通心滴丸可进一步改善AMI患者PCI术后心功能、抑制心室重构，且安全性良好。目的：探讨麝香通心滴丸联合沙库巴曲缬沙坦片对急性心肌梗死（AMI）经皮冠状动脉介入治疗（PCI）术后患者心功能及心室重构的影响。方法：纳入40例AMI行PCI且合并早发心力衰竭的患者，随机分为对照组（20例，常规西药含沙库巴曲缬沙坦片）和观察组（20例，沙库巴曲缬沙坦片联合加用麝香通心滴丸，2丸/次，3 次/d），治疗3个月。比较两组治疗前后BNP、NYHA分级、LVEF、LVEDD、LVESD、LVMI。结果：观察组BNP、 LVEDD、LVESD、LVMI均低于对照组，LVEF、NYHA改善率均高于对照组（P < 0.05）；两组均无严重不良反应。结论：联合麝香通心滴丸可进一步改善AMI患者PCI术后心功能、抑制心室重构，且安全性良好。

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

张萍萍 (2026) conducted an RCT in Acute myocardial infarction after PCI complicated with early-onset heart failure (n=40). Shexiang Tongxin Dropping Pills plus Sacubitril/Valsartan and standard therapy vs. Standard therapy including Sacubitril/Valsartan (50-200 mg twice daily), dual antiplatelet therapy, statin, and beta-blocker was evaluated on NYHA functional class improvement (≥1 grade) at 3 months (p=0.028).

synapsesocial.com/papers/6af354495b67d29976ea07b5 https://doi.org/10.37155/2717-5693-0702-4

View Full Paper

Ask AI

Bookmark

Share

麝香通心滴丸联合沙库巴曲缬沙坦片对急性心肌梗死pci术后患者心功能及心室重构的影响

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

麝香通心滴丸联合沙库巴曲缬沙坦片对急性心肌梗死pci术后患者心功能及心室重构的影响

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading